Deals & Cases
Schellenberg Wittmer advised Boehringer Ingelheim on its acquisition of Evax AG
25.08.2026
Schellenberg Wittmer advised Boehringer Ingelheim, one of the largest pharmaceutical companies, on the acquisition of Evax AG. Evax AG is a Swiss biotech company focused on equine health.
The Schellenberg Wittmer team consisted of Pascal Hubli (overall lead), Florian Angstmann, Olivia Wipf, Filip Majernik, Nanina Lätsch and Caroline Genz (all Corporate / M&A), Philipp Groz and Alisa Zehner (both IP / Life Sciences), Petra Spring and Rachel Pawlik (both Employment), Roland Mathys and Jacqueline Brunner (both ICT / Data Protection) as well as Josef Caleff and Klaudia Bibaj (both Real Estate).
